Literature DB >> 8206620

Structural remodeling in hypertensive heart disease and the role of hormones.

K T Weber1, Y Sun, E Guarda.   

Abstract

In hypertension, the risk of adverse cardiovascular events, including heart failure, is increased in the presence of left ventricular hypertrophy. Morphological studies suggest that it is not the quantity but rather the quality, or structure, of myocardium that confers such risk. Iterations in tissue structure that appear in hypertensive heart disease include a remodeling of intramyocardial coronary arterioles, similar to that found in systemic organs, and a disproportionate accumulation of fibrillar collagen within their adventitia and neighboring interstitial space. Microscopic scars replacing necrotic cardiac myocytes are also evident. These expressions of fibrosis appear in the normotensive, nonhypertrophied right and hypertensive, hypertrophied left ventricles and are linked to the renin-angiotensin-aldosterone system. Cardiac myocyte growth, the major determinant of myocardial mass, is related to ventricular loading. Mechanisms responsible for the reactive and reparative fibrosis with renin-angiotensin-aldosterone system activation are under investigation. In vitro quantitative autoradiography has identified angiotensin II, aldosterone, endothelin, and bradykinin receptors in the myocardium. A nonendothelial tissue angiotensin-converting enzyme, whose binding density is marked in the matrix of heart valves, adventitia, and sites of fibrosis, irrespective of its pathogenic basis, has also been found. This angiotensin-converting enzyme may be responsible for regulating local concentrations of angiotensin II and bradykinin that govern fibroblast collagen turnover. Based on a paradigm of discordant reciprocal regulation, in which a relative abundance of stimulators (eg, angiotensin II, aldosterone, and endothelins) of collagen synthesis exceeds inhibitors (eg, bradykinin, prostaglandins, and glucocorticoids), fibrous tissue appears.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8206620     DOI: 10.1161/01.hyp.23.6.869

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  32 in total

1.  Diastolic Heart Failure.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-10

2.  Role of the angiotensin II receptor blocker valsartan in heart failure.

Authors:  R L Webb; M de Gasparo
Journal:  Exp Clin Cardiol       Date:  2001

3.  Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling.

Authors:  Ana Patrícia Fontes-Sousa; Carmen Brás-Silva; Ana Luísa Pires; Daniela Monteiro-Sousa; Adelino F Leite-Moreira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-14       Impact factor: 3.000

4.  Treating relentlessly progressive congestive heart failure: what next?

Authors:  J T Willerson; R Delgado; D Mann
Journal:  Tex Heart Inst J       Date:  1998

5.  Calcium handling proteins: structure, function, and modulation by exercise.

Authors:  Jamille Locatelli; Leonardo V M de Assis; Mauro C Isoldi
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

Review 6.  Chronic heart failure and the immune system.

Authors:  Daniela Mari; Federica Di Berardino; Massimo Cugno
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

7.  Two-layer model of coronary artery vasoactivity.

Authors:  Yunlong Huo; Xuefeng Zhao; Yana Cheng; Xiao Lu; Ghassan S Kassab
Journal:  J Appl Physiol (1985)       Date:  2013-03-07

8.  Clinical and Pre-clinical Applications of the Transcendental Meditation Program in the Prevention and Treatment of Essential Hypertension and Cardiovascular Disease in Youth and Adults.

Authors:  Vernon A Barnes; David W Orme-Johnson
Journal:  Curr Hypertens Rev       Date:  2006-08-01

Review 9.  Current Management and Future Directions of Heart Failure With Preserved Ejection Fraction: a Contemporary Review.

Authors:  Chayakrit Krittanawong; Marrick L Kukin
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-20

10.  Angiotensin II-activated protein kinase D mediates acute aldosterone secretion.

Authors:  Brian A Shapiro; Lawrence Olala; Senthil Nathan Arun; Peter M Parker; Mariya V George; Wendy B Bollag
Journal:  Mol Cell Endocrinol       Date:  2009-12-02       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.